The global biomaterials market is predicted to reach more than $173 billion by 2022, growing at a 16 percent compound annual growth rate, according to a Market Research Engine report.

More and more surgeons are beginning to talk about biologics, stem cells and regenerative medicine. Sameer Mathur, MD, an orthopedic surgeon, explains the future of stem cells in a sponsored article with WRAL.com.

Bert Mandelbaum, MD, described the evidence supporting orthobiologic treatments for torn anterior cruciate ligaments in a Medscape column.

Anika Therapeutics will showcase its Hyalofast cartilage repair scaffold at the 2019 International Cartilage Repair Society Summit in San Diego, Jan. 17-18.

Hughston Clinic of Columbus (Ga.) orthopedic surgeon Champ Baker Jr., MD, implemented Lipogems technology to help repair patients' damaged tissue.

SPR Therapeutics appointed Peter Staats, MD, to chief medical advisor.

Stuart Miller, MD, is an orthopedic surgeon at MedStar Union Memorial Hospital and assistant professor at Johns Hopkins University School of Medicine, both based in Baltimore.

Biogennix named Michael Roux as the orthobiologic company's new general manager.

The global platelet rich plasma market is expected to hit $400 million by 2023, growing at a 13.3 percent compound annual growth rate, according to a Qurate Business Intelligence report.

The global orthopedic biomaterials market is expected to grow at a 7 percent compound annual growth rate between 2018 and 2022, according to a Technavio report.

Bioventus launched its Osteomatrix+ bone graft for various spine and orthopedic applications.

Orthopedic fixation company Ossio received FDA 510(k) clearance for its Ossiofiber Bone Pin Family.

Marco Rodriguez, MD, founder of Baton Rouge, La.-based International Spine Institute, is using regenerative stem cell therapies as an alternative to spinal surgery.

Generex Biotechnology Corp. signed a letter to purchase Medisource Partners, an FDA-registered distributor.

SpinalCyte received a new Australian patent related to its fibroblast technology.

DiscGenics' injectable disc cell therapy, IDCT, passed the initial safety review of its first-in-human trial for moderate degenerative disc disease treatment.

JRF Ortho provides allograft joint repair solutions.

The FDA granted StemCyte permission to proceed with its phase 2 investigational new drug application for the Allogenic Human Leukocyte Antigen-Matched Umbilical Cord Blood Mononuclear Stem Cells (MC001).

Carmell Therapeutics, a developer of plasma-based bioactive materials to accelerate bone and soft tissue healing, welcomed Wendy DiCicco to its board of directors.

The Department of Defense granted a team of researchers at the University of Arizona in Tucson $2 million to study bone regrowth technology, according to The Brunswick News.